An important new collection of clinical and preclinical reports on genetic therapy, this book describes illustrative examples of diseases in which gene-based interventions are presently plausible, and presents case studies of current research usingMoreAn important new collection of clinical and preclinical reports on genetic therapy, this book describes illustrative examples of diseases in which gene-based interventions are presently plausible, and presents case studies of current research using both synthetic oligonucleotides and biological vectors.Combining the insights of over 50 contributors, Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectorsfurnishes a historical overview of genetic therapyhighlights official Food and Drug Administration positions on the preparation of oligonucleotides and vectorsoffers practical models of agent preparation, animal testing, pharmacokinetics, toxicology, and clinical trialsdiscusses both synthetic DNA and biological vector approaches to ...
Genetic Therapy essay writing service, custom Genetic Therapy papers, term papers, free Genetic Therapy samples, research papers, help
Definition of angiogenic gene therapy in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is angiogenic gene therapy? Meaning of angiogenic gene therapy as a finance term. What does angiogenic gene therapy mean in finance?
Genetic Therapy Inc., the Gaithersburg biotechnology company, and its parent, Sandoz AG, launched a pivotal, large-scale clinical trial yesterday of what the companies hope will prove a
Learn about genetic therapies, including gene transfer and genome editing, and how NHLBI research aims to treat, prevent, or cure conditions caused by problems in your DNA.
You should also consider enrolling in "My Retina Tracker", a free registry that helps link people with retinal disease to appropriate clinical trials that are recruiting. For more information on "My Retina Tracker" please see the following web link: https://www.myretinatracker.org/. Below is a list of companies that are developing treatments for Stargardt Disease:. Sanofi (http://en.sanofi.com/index.aspx) Gene therapy offers a viable alternative to pharmaceutical therapy. With gene replacement therapy, a normal ABCA4 gene is introduced into photoreceptor cells to supplant the function of the defective gene. FFB-supported scientist, Dr. Rando Allikmets, was the first individual to show that a lentivirus could be used to deliver a normal ABCA4 gene into photoreceptor cells of the ABCA4 mutant mouse. Dr. Allikmets gene therapy studies have led to a collaboration between Sanofi and the Foundation Fighting Blindness to develop a gene therapy treatment Stargardt disease. A Phase I/II human clinical ...
What is the current status of gene therapy research?. The Food and Drug Administration (FDA) has not yet approved any human gene therapy product for sale. Current gene therapy is experimental and has not proven very successful in clinical trials. Little progress has been made since the first gene therapy clinical trial began in 1990. In 1999, gene therapy suffered a major setback with the death of 18-year-old Jesse Gelsinger. Jesse was participating in a gene therapy trial for ornithine transcarboxylase deficiency (OTCD). He died from multiple organ failures 4 days after starting the treatment. His death is believed to have been triggered by a severe immune response to the adenovirus carrier.. Another major blow came in January 2003, when the FDA placed a temporary halt on all gene therapy trials using retroviral vectors in blood stem cells. FDA took this action after it learned that a second child treated in a French gene therapy trial had developed a leukemia-like condition. Both this child ...
Dr. Changfa Guo, professor Chunsheng Wang and their co-investigators from Zhongshan hospital Fudan University, Shanghai, China have established a novel hyperbranched poly(amidoamine) nanoparticle based hypoxia regulated vascular endothelial growth factor gene therapy strategy which is an excellent substitute for the current expensive and uncontrollable VEGF gene delivery system. This discovery, reported in the June 2012 issue of Experimental Biology and Medicine, provides an economical, feasible and biocompatible gene therapy strategy for cardiac repair.
Evidence to support the effective use of chromatin insulators-a class of DNA regulatory elements-to improve the expression and safety of gene transfer vectors is the focus of the Methods Review by David Emery entitled "The Use of Chromatin Insulators to Improve the Expression and Safety of Integrating Gene Transfer Vectors.". "Bone marrow-directed gene therapy was the first model considered in the treatment of genetic diseases and remains one of the most successful models in terms of clinical efficacy," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.. Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies is an authoritative peer-reviewed journal published ...
Gene therapy research in Type 2 Gaucher disease. Information for patients, relatives, doctors and researchers on Gauchers disease from the independent charity The Gauchers Association
The eye is an easily accessible, highly compartmentalised and immune-privileged organ that offers unique advantages as a gene therapy target. Significant advancements have been made in understanding the genetic pathogenesis of ocular diseases, and gene replacement and gene silencing have been implicated as potentially efficacious therapies. Recent improvements have been made in the safety and specificity of vector-based ocular gene transfer methods. Proof-of-concept for vector-based gene therapies has also been established in several experimental models of human ocular diseases. After nearly two decades of ocular gene therapy research, preliminary successes are now being reported in phase 1 clinical trials for the treatment of Leber congenital amaurosis. This review describes current developments and future prospects for ocular gene therapy. Novel methods are being developed to enhance the performance and regulation of recombinant adeno-associated virus- and lentivirus-mediated ocular gene ...
Researchers significantly reduced HIV levels in mice with a genetic therapy that induces immune cells to better fight the virus. Publishing their results in Molecular Therapy, researchers engineered a molecule known as a chimeric antigen receptor (CAR) and inserted a gene for that molecule into blood-forming stem cells, which they transplanted into mice genetically engineered to have human immune systems.. The CAR is a two-part receptor that recognizes an antigen (such as HIV) and in this case instructs immune cells to locate and kill HIV-infected cells. Blood-forming stem cells give rise to all kinds of blood cells, including immune cells.. The transplant of the CAR-carrying blood stem cells gave rise to functional immune cells that could kill HIV in the mice. Consequently, the mice experienced an 80 to 95 percent drop in viral load.. The researchers concluded that such a genetic therapy may be feasible in HIV-positive humans. They also believe this therapeutic technique may be used to fight ...
This is a Phase I/II clinical trial of ex vivo hematopoietic stem cell (HSC) gene therapy for X-linked severe combined immunodeficiency (XSCID). XSCID results from defects in the IL2RG gene encoding the common gamma chain (gc) shared by receptors for Interleukin 2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. XSCID patients generally lack T-lymphocytes and NK cells, and their B-lymphocytes fail to make essential antibodies. XSCID is fatal in infancy without immune reconstitution, such as by allogeneic bone marrow transplantation (BMT). However, many transplanted patients achieve only partial immune reconstitution, and consequently have recurrent infections, autoimmunity and/or poor growth. Recent successful retroviral gene therapy instead of BMT for infants with XSCID indicates that ex vivo gene therapy can provide clinical benefit to XSCID patients.. We will enroll eight older XSCID patients (1.5-20 years-old; greater than or equal to 12 kg body weight), who have had attempted BMT, but who have ...
Dr. Boye reported that the landmark gene therapy clinical trial for people with LCA (RPE65 mutations) at the Childrens Hospital of Philadelphia (CHOP) has progressed from Phase I/II to Phase III. This moves the therapy a step closer to market approval from the U.S. Food and Drug Administration.. In collaboration with the University of Iowa, the investigators will treat people with better vision than those in the Phase I/II study, as well as children as young as 3. Children as young as 8 were treated in the Phase I/II study.. Also, the patients will receive injections to both eyes over a weeks time. In Phase I/II, second eyes were treated several months after the first eyes.. Sixteen people will receive the therapy in Phase III, and eight will receive a placebo injection. By comparing the treatment group with controls, scientists will get a better sense of how the treatment is affecting the eye. People receiving the placebo will be given the treatment a year later.. Choroideremia. Six patients ...
After success in animal studies with individual muscle therapy, researchers find that delivering the gene to the whole body may be effective as well.
Examples of these cutting-edge methods are presented in a series of five provocative articles in the latest issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The articles are available free online.. Barese and Dunbar highlight the advances in gene marking techniques that are enabling selection and targeting of specific immune cell populations for cell and gene therapy. The success of marking studies will help optimize gene transfer for immunotherapeutics and improve patient survival, conclude the authors in the review article "Contributions of Gene Marking to Cell and Gene Therapies.". Giordano et al. explore the use of PCR and next-generation DNA sequencing methods to identify specific gene products that are associated with successful long-term transfer of therapeutic genes to bone marrow. They report their findings in the research article entitled "Clonal Inventory Screens Uncover Monoclonality Following Serial Transplantation of MGMTP140K-Transduced Stem ...
FILE - In this Oct. 4, 2017, file photo, Dr. Albert Maguire, right, checks the eyes of Misa Kaabali, 8, at the Childrens Hospital of Philadelphia. Misa was 4-years-old when he received his gene therapy treatment. The first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but its still among the most expensive genetic therapies in the world. Spark Therapeutics said it decided on the lower price tag for Luxturna, after hearing from health insurers about their ability to cover the injectable treatment. less ...
According to a new research report by RNCOS entitled, Global Gene Therapy Market Analysis, globally various geographies are growing in their gene therapy applications out of which US is showing dynamic research and development activity. The FDA too is actively involved in overseeing this activity and has received many requests from medical researchers and manufacturers to study gene therapy and develop gene therapy products. The number of gene therapy based trials done in US till date rank over 1000 which is very promising to the industrys growth and innovation. Several companies in US have also been actively found to enter into strategic co-operation to facilitate gene therapy research in the country.. With the entry of new gene therapy products such as Glybera, this biotech niche is expected to capture major market attention. According to latest report by RNCOS, Global Gene Therapy Market Analysis, the gene therapy advanced stage trial products such as Collategene, Allovectin-7 and Generx are ...
According to a new research report by RNCOS entitled, Global Gene Therapy Market Analysis, globally various geographies are growing in their gene therapy applications out of which US is showing dynamic research and development activity. The FDA too is actively involved in overseeing this activity and has received many requests from medical researchers and manufacturers to study gene therapy and develop gene therapy products. The number of gene therapy based trials done in US till date rank over 1000 which is very promising to the industrys growth and innovation. Several companies in US have also been actively found to enter into strategic co-operation to facilitate gene therapy research in the country.. With the entry of new gene therapy products such as Glybera, this biotech niche is expected to capture major market attention. According to latest report by RNCOS, Global Gene Therapy Market Analysis, the gene therapy advanced stage trial products such as Collategene, Allovectin-7 and Generx are ...
Researchers have demonstrated the long term safety and benefit of a virus-based gene therapy that has been applied for the first time in a clinical setting.
Buy, download and read Non-viral Gene Therapy ebook online in PDF format for iPhone, iPad, Android, Computer and Mobile readers. Author: Kazunari Taira; Kazunori Kataoka; Takuro Niidome. ISBN: 9784431278795. Publisher: Springer Japan. Several years ago, when the discovery of catalytic RNA was recognized in a public manner,many people asked if new ?elds of therapy would soon be available. Although some tentative positive answers wer
Press Release issued Dec 9, 2014: The gene therapy market has undergone a series of transformation from past few years. Initially gene therapy of monogenetic diseases was popular; however now the gene therapy market is gaining popularity for treatment of cancer. Cancer gene therapy refers to a process of treatment of cancer by inserting therapeutic DNA into patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of gene. Other technique involves inactivation of a gene that is not working properly. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells.
WASHINGTON - A first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but its still among the most expensive genetic therapies in the world.. Spark Therapeutics says it decided on the lower price tag for Luxturna (Lux-turn-a) after hearing concerns from health insurers about their ability to cover the injectable treatment.. Consternation over skyrocketing drug prices, especially in the U.S., has led to intense scrutiny from patients, Congress, insurers and hospitals.. "We wanted to balance the value and the affordability concerns with a responsible price that would ensure access to patients," said CEO Jeffrey Marrazzo, in an interview with The Associated Press.. Luxturna is still significantly more expensive than nearly every other drug on the global market, including two other gene therapies approved earlier last year in the U.S. Approved last month, Luxturna, is the nations first gene therapy for an inherited disease. ...
TY - JOUR. T1 - Nanoparticles for cancer gene therapy. T2 - Recent advances, challenges, and strategies. AU - Wang, Kui. AU - Kievit, Forrest M.. AU - Zhang, Miqin. PY - 2016/12/1. Y1 - 2016/12/1. N2 - Compared to conventional treatments, gene therapy offers a variety of advantages for cancer treatment including high potency and specificity, low off-target toxicity, and delivery of multiple genes that concurrently target cancer tumorigenesis, recurrence, and drug resistance. In the past decades, gene therapy has undergone remarkable progress, and is now poised to become a first line therapy for cancer. Among various gene delivery systems, nanoparticles have attracted much attention because of their desirable characteristics including low toxicity profiles, well-controlled and high gene delivery efficiency, and multi-functionalities. This review provides an overview on gene therapeutics and gene delivery technologies, and highlight recent advances, challenges and insights into the design and the ...
Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice. This is the first time that genome editing, which precisely targets and repairs a genetic defect, has been done in a living animal and achieved clinically meaningful results.
Our overall goal is to file an IND within 4 years for a hematopoietic stem cell based genetic therapy for HIV-1 disease. The concept is that introducing anti-HIV gene therapeutics into hematopoietic stem cells will produce a protected population of T lymphocytes and monocyte/macrophages (the cells specifically infected by HIV) in individuals to decrease viral load and maintain stable T lymphocyte counts. Hemapoietic stem cells are unique in that they are multipotent stem cells that give rise to all the types of blood cells, including T cells and monocytes/macrophages. During the first year we have met each of our key milestones and made significant progress in identifying and testing genetic reagents combined in the context of a lentiviral vector for stable delivery into hematopoietic stem cells. The vector candidates include combinations of gene therapeutics aimed at different stages of HIV replication namely: i) binding to the CCR5 HIV co-receptor (RNA interference to down-regulate CCR5), ii) ...
News about the Mueller Lab for Gene Therapy including recent publications, ongoing gene therapy research, events attended by the Lab.
Sometimes I fear science is creating genetically superior mice who will one day take over the world. Not too long ago, I talked about a neuroscientist who had
The pre-implantation genetic analysis is a set of examinations which can help as reveal genetic abnormalities of embryo before it is transferred to the mother.
LONDON (AP) The European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure diseases. In a statement on Friday, the EMA said Glybera, made by Dutch company uniQure, should be approved across Europe for the treatment of an ext.....
AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells. As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34+) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme). In vitro analysis of these gene-modified cells showed no differences in their hematopoietic potential compared with nontransduced cells. In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to ~1% over 4 weeks of culture. Ethical study design required that patients be transplanted with both gene-modified and unmanipulated hematopoietic progenitor cells obtained from the patient by apheresis. Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no ...
Press Release issued May 30, 2014: Reportstack, provider of premium market research reports announces the addition of Cancer Gene Therapy Market Analysis market report to its offering The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to
Scope. - Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success:. - Why do gene therapies still occupy only a minimal market share in their respective indications?. - What can be learned from the gene therapies that have already reached the market?. - A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies:. - What are the relative advantages and disadvantages of each vector type and which hold the most promise?. - What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?. - The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene:. - In which therapy areas is there the highest level of R&D activity for gene therapies?. - t which stage of development does the ...
Information resource for gene therapy news, clinical trials, guidelines, regulation, literature, databases, background and educational information, scientific research articles, clinical trial databases and more gene therapy information
The report, which was published in the journal Nature, shows that the monkeys were protected from all HIV types for up to 34 weeks. It also showed that even chronically infected monkeys benefited from the vaccine which leads researchers to believe the approach could prove useful in already infected people.. Prof Michael Farzan, lead researcher, said, "We are closer than any other approach to universal protection, but we still have hurdles, primarily with safety for giving it to many, many people. Were very proud of it and we think its a big deal, but we are biased.". Up to now, vaccines against HIV struggle because the virus mutates so quickly, constantly shifting targets. This new vaccine targets the areas that the virus tries to change.. Professor Farzan explains, "The real strength of this thing is that it is more potent than any antibody." But there are safety concerns. During traditional vaccinations, the immune system responds after its been presented with a threat. The new gene therapy ...
...PHILADELPHIA A gene therapy study focused on finding a cure for a rar...The results of the most recent phase of the study for Lebers Congenit... The data from our study has already been used to develop additional c...Published in 2012 the winning studies are the latest in a long tradit...,Penn,receives,prestigious,national,award,for,breakthrough,in,gene,therapy,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Modifying stem cells by insertion of anti-HIV gene or gene editing technologies can theoretically result in an HIV proof immune system in patients after stem ce...
Information resource for gene therapy news, clinical trials, guidelines, regulation, literature, databases, background and educational information, scientific research articles, clinical trial databases and more gene therapy information
Scientists from The University of Manchester have used stem cell gene therapy to treat a fatal genetic brain disease in mice for the first time. The method was used to treat Sanfilippo - a fatal inherited condition which causes progressive dementia in children - but could also benefit several neurological, genetic diseases. Researchers beh...
Glioblastoma (GBM) is the most aggressive form of brain cancer, with a dismal prognosis and extremely low percentage of survivors. Novel therapies are in dire need to improve the clinical management of these tumors and extend patient survival. Genetic therapies for GBM have been postulated and attempted for the past twenty years, with variable degrees of success in pre-clinical models and clinical trials. Here we review the most common approaches to treat GBM by gene therapy, including strategies to deliver tumor-suppressor genes, suicide genes, immunomodulatory cytokines to improve immune response, and conditionally-replicating oncolytic viruses. The review focuses on the strategies used for gene delivery, including the most common and widely used vehicles (i.e., replicating and non-replicating viruses) as well as novel therapeutic approaches such as stem cell-mediated therapy and nanotechnologies used for gene delivery. We present an overview of these strategies, their targets, different advantages,
Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain
Gene therapy is a rapidly growing field of medicine in which genes are introduced into the body to treat diseases. Genes control heredity and provide the basic biological code for determining a cells specific functions. Gene therapy seeks to provide genes that correct or supplant the disease-controlling functions of cells that are not, in essence, doing their job. Somatic gene therapy introduces therapeutic genes at the tissue or cellular level to treat a specific individual. Germ-line gene therapy inserts genes into reproductive cells or possibly into embryos to correct genetic defects that could be passed on to future generations. Initially conceived as an approach for treating inherited diseases, like cystic fibrosis and Huntingtons disease, the scope of potential gene therapies has grown to include treatments for cancers, arthritis, and infectious diseases. Although gene therapy testing in humans has advanced rapidly, many questions surround its use. For example, some scientists are ...
Boot-Hanford, a reader in molecular biology, is leading the research programme We are still very much at the research stage, but if all ...
The objective of this protocol is to reinitiate an ex vivo gene therapy clinical protocol to treat patients with SCID-X1 without HLA identical family donor nor HLA identical unrelated donor (bone marrow and cord blood) available in an adequate time with the clinical conditions of the patient at diagnosis (approximately 6 weeks). This clinical protocol No. 2 of SCID-X1 must be as efficient than the previous one but must involve a risk of insertional mutagenesis significantly reduced as compared to the first protocol.. The main purpose of the study is the study of toxicity: tolerance and incidence of serious adverse effects.. Secondary goals are the evaluation of immune reconstitution allowing the cure of infections present at the time of gene therapy, assessment of integration sites, and finally the long-term correction of immunosuppression.. ...
Tiny wound-up circular bits of DNA that carry a short "hairpin" of RNA could prove a solution to the quest for a non-toxic, long-lived gene therapy vector designed to silence cancer genes in tumor cells, said researchers from Baylor College of Medicine and The Methodist Hospital Research Institute in a report that appears in the current issue of the journal Gene Therapy.. At a minimum, this Minivectorâ" ¢ DNA will prove a valuable laboratory tool, said Dr. Lynn Zechiedrich, associate professor of molecular virology and microbiology at BCM and one of the reports senior authors. "In the best case scenario, it could prove a valuable therapeutic tool that can work on cells that are difficult to manipulate. This may help clinicians treat some diseases.". Minivector DNA avoids the toxicity of viruses, lasts longer than plasmids (large DNA circles containing bacterial sequences toxic to human cells) and survives and continues gene delivery longer than small interfering RNAs (siRNA), currently used ...
In 2008, European clinical trials began on twelve children suffering from Progeria. The treatment is based on a combination of two existing molecules: statins (prescribed in the treatment and prevention of atherosclerosis and cardiovascular risks) and aminobisphosphonates (prescribed in to treat osteoporosis and to prevent complications in some forms of cancer). The use of both these molecules aims to chemically alter progerin to reduce its toxicity. However, although this treatment aimed to slow down the development of the disease, it did not reduce the quantities of progerin. To study this aspect, researchers needed to obtain a relevant animal model. An "authentic" Progeria model… To generate a model of this kind, Spanish and French researchers decided to introduce a gene mutation (G609G), equivalent to that identified in humans (G608G), in mice to reproduce the exact pathological mechanism found in the children, with a view to then blocking it. The mice models were created under the ...
Abstract: The paperhighlights the new trends in gene therapy research area and clinical trials. It should benoted that the majority of firms involved in development of the scientific approaches togene therapy are concentrated in the United States. The investments of the given companieson development and research of new genetic constructs also delivery systems make hundredmillions dollars. The greatest part (more than 80 %) of gene therapy clinical trialsprojects are also connected with the US research departments; the majority of them isrelated to tumor therapy. The advantages and drawbacks of the main methods of nucleicacids delivery to the cells are considered; diseases that are attempted to be treatedusing gene therapy methods are listed. A special attention of the review is devoted to themodern stand in research on cell and Duchenne muscular dystropy (DMD) gene therapy, alsobrief description of basic results achieved in the authors laboratory is given. Basicoriginal results of transfection ...
Welcome to Localized Therapeutics, LLC!. SUMMARY: Gene therapy is a promising field which got a recent regulatory boost with the approval of first gene therapy drug in Europe. We are developing laser-controlled gene switches for gene therapy drugs. This will allow to repeatedly activate therapeutic genes in target organs when desired by turning on light at desired times in wearable multi-laser patches. This is way safer than traditional drugs or traditional gene therapy drugs.. OUR TECHNOLOGY. Our main focus is to make gene therapy safer and more efficient by driving transgene expression with laser light. Gene therapy is a new field of medicine which has great promise for treatment of cancer, arthritis, obesity and many other disorders. Instead of traditional small molecule drugs, gene therapy uses DNA vectors made from safe viruses incapable of multiplying. Gene therapy drugs dont have side effects typical for traditional chemical drugs. Nonetheless, until now, there was no good way to control ...
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
Health,...But research is preliminary and more trials are needed study says ...SUNDAY Feb. 15 (HealthDay News) -- Researchers are reporting promisin... We know it works but we need to make it better before we launch a la...Existing treatments work fairly well for many people with HIV the vir...,Gene,Therapy,Holds,Promise,for,HIV,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news